CervoMed Inc.
CRVO
NASDAQ·Healthcare·Biotechnology·Mkt cap $24.1M
$2.60
▼ -1.52%
P/E
—
Mkt Cap
$24.1M
52-Wk Range
$2.13–$10.89
52-Week Range
$2.13 - $10.89
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 73.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary brain-penetrant small molecule technology
- Focused pipeline in underserved neurodegenerative disease markets
- Experienced management team in clinical-stage biotechnology
- Oral administration advantage over injectable competitors
Bear Case
1 risk
- Low volatility (beta -4.3).
Growth
Revenue decline expected
Successful advancement of neflamapimod through clinical trials
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-16.4% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying CRVO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 7, 2026
Reported EPS of -$0.64 vs -$0.87 consensus (+26.4% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+26.4%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$322.6K
$0
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · $9.00 · May 18, 2026
vs Industry
How CRVO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related